Background
Endocrine-disrupting chemicals can interfere with hormonal homeostasis and have adverse effects for both humans and the environment. Their identification is increasingly difficult due to lack of adequate toxicological tests. This difficulty is particularly problematic for cosmetic ingredients, because in vivo testing is now banned completely in the European Union. Objectives: The
Discussion
These data support the concerns of regulatory authorities about the endocrine-disrupting potential of preservatives. These data also define the need to further determine their effects on the endocrine system and the need to reassess the risks they pose to human health and the environment. https://doi.org/10.1289/EHP6596.
Methods
We screened preservatives listed in Annex V in the European Union Regulation on cosmetic products to predict their binding to nuclear receptors using the Endocrine Disruptome and VirtualToxLab™ version 5.8 in silico tools. Five candidate preservatives were further evaluated for androgen receptor (AR), estrogen receptor (ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math>), glucocorticoid receptor (GR), and thyroid receptor (TR) agonist and antagonist activities in cell-based luciferase reporter assays in vitro in AR-EcoScreen, hERα-HeLa-9903hERα-HeLa-9903<math><mrow><mtext>hER</mtext><mi>α</mi><mtext>-HeLa-</mtext><mn>9903</mn></mrow></math>, MDA-kb2, and GH3.TRE-Luc cell lines. Additionally, assays to test for false positives were used (nonspecific luciferase gene induction and luciferase inhibition).
Results
Triclocarban had agonist activity on AR and ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math> at 1μM1μM<math><mrow><mn>1</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> and antagonist activity on GR at 5μM5μM<math><mrow><mn>5</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> and TR at 1μM1μM<math><mrow><mn>1</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>. Triclosan showed antagonist effects on AR, ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math>, GR at 10μM10μM<math><mrow><mn>10</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> and TR at 5μM5μM<math><mrow><mn>5</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>, and bromochlorophene at 1μM1μM<math><mrow><mn>1</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> (AR and TR) and at 10μM10μM<math><mrow><mn>10</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> (ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math> and GR). AR antagonist activity of chlorophene was observed [inhibitory concentration at 50% (IC50) IC50=2.4μMIC50=2.4μM<math><mrow><msub><mrow><mrow><mtext>IC</mtext></mrow></mrow><mrow><mrow><mn>50</mn></mrow></mrow></msub><mo>=</mo><mn>2.4</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>], as for its substantial ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math> agonist at >5μM>5μM<math><mrow><mo>></mo><mn>5</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math> and TR antagonist activity at 10μM10μM<math><mrow><mn>10</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>. Climbazole showed AR antagonist (IC50=13.6μMIC50=13.6μM<math><mrow><msub><mrow><mrow><mtext>IC</mtext></mrow></mrow><mrow><mrow><mn>50</mn></mrow></mrow></msub><mo>=</mo><mn>13.6</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>), ERαERα<math><mrow><mtext>ER</mtext><mi>α</mi></mrow></math> agonist at >10μM>10μM<math><mrow><mo>></mo><mn>10</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>, and TR antagonist activity at 10μM10μM<math><mrow><mn>10</mn><mspace></mspace><mi>μ</mi><mi>M</mi></mrow></math>.
